CEP-1347 is a semi-synthetic compound shown to protect multiple nerve cell types from a variety of insults leading to programmed cell death (apoptosis) which could improve the survival of dopamine...
- Mechanism
- Curator reviewed
CEP-1347, an orally active molecule, is a selective and potent inhibitor of the stress-activated protein kinase pathway, an intracellular signaling pathway that is an essential component of the stress response leading to neuronal death. In-vitro cell culture systems and in-vivo mouse and non-human primate models of Parkinson's disease have shown that CEP-1347 protects dopamine neurons in the substantia nigra, the area of the brain affected by Parkinson's disease.
- Primary indication
- Investigated for use/treatment in asthma and parkinson's disease.Curator reviewed
- Formula / weight
- C33H33N3O5S2 · 615.762 g/mol (avg)
- Code names
- CEP-1347
Resolves to
WMBUVOLZSWTKMP-KQFGJPIXSA-NSMILES[H][C@@]12C[C@H](C(=O)OOC)[C@](C)(O1)N1C3=C(C=C(CSCC)C=C3)C3=C4CNC(=O)C4=C4C5=C(C=CC(CSCC)=C5)N2C4=C13What you can answer from here — as of June 15, 2026
Which drugs share a target with CEP-1347, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account